Information on medicines impacted by nitrosamine impurities
Necessary actions have been taken to stop the supply or remove products that contain nitrosamine impurities above the acceptable levels from the Singapore market. To ensure patients’ continued access to essential medicines, we have also temporarily allowed continued supply of certain medicines that may contain trace amount of nitrosamine impurities above acceptable levels while companies make the necessary changes to eliminate or reduce the nitrosamines to acceptable levels. The list of medicines impacted are in Tables 1 and 2 below.
There is no immediate risk associated with the use of medicines containing trace levels of nitrosamine impurities. Nitrosamine impurities are probable carcinogens based on animal studies where they have been reported to cause cancer only if consumed in very high amounts over a long period of time. The potential risk of cancer is with long-term exposure to unacceptable levels of the impurities.
A very conservative approach is used to set limits for these impurities in medicines, based on what is considered as reasonably safe if a patient continues to take the affected medicine every day for a lifetime of 70 years.
Patients are advised to speak to their doctor or healthcare professional if they have concerns about this issue and should not stop the medicines which has been prescribed to them for their medical conditions on their own. Sudden stopping of the medicines may pose a greater and more immediate health risk than the potential exposure to nitrosamine impurities.
Table 1: Medicines recalled due to nitrosamine impurities
Medicine
Use
Link to product recall information – Recall date
Acyclovir
Chickenpox, shingles, herpes simplex virus infection
27 Apr 2022
1 Aug 2022
16 Aug 2023
Amitriptyline
Depression
6 Feb 2023
Angiotensin II receptor blockers (ARBs) (e.g., candesartan, irbesartan, losartan, olmesartan, valsartan)
High blood pressure
28 Mar 2019
Fluoxetine
Depression, bulimia nervosa, obsessive compulsive disorder, premenstrual dysphoric disorder
27 Sep 2023
18 Sep 2024
25 Sep 2024
Metformin
Type 2 diabetes mellitus
4 Dec 2019
Ranitidine
Indigestion, heartburn, gastric ulcers
16 Sep 2019
Salbutamol
Asthma, chronic bronchitis, emphysema
9 Dec 2021
Sitagliptin
13 Dec 2022
Varenicline
Smoking cessation
16 Nov 2021
Table 2: Medicines that may contain nitrosamine impurities above acceptable levels temporarily allowed for supply
Publication date
Rifampicin
Tuberculosis
23 Apr 2021
2 Nov 2022
Ropinirole
Parkinson’s disease
14 Jun 2023
Regulatory overview
Register your product
Apply for post-approval variation
Reclassify your product
Dealer's licensing and certification
Retain, cancel or transfer product registration
Risk management plan requirements
Report adverse events
Report or recall defective products
Retail pharmacy licensing
Clinical trials
Product consultation
Advertisements and promotions
CPP and SLS
International collaboration
Medicines quality and compliance monitoring
Listing of approvals and post-registration actions
Guidance documents
Fees and turnaround time
PRISM (Therapeutic products)
Infosearch